Articles On Imugene (ASX:IMU)

There have been a couple of big moves in the betting industry on Wednesday following the release of quarterly updates. Let's dig a little deeper into these releases now and see what's getting investors excited: Bluebet Holdings Ltd (ASX: B...

If you're the type of investor that likes high risk-high reward investments, then read on. That's because a leading broker is tipping an ASX biotech stock to almost double in value over the next 12 months. The company in question is Imugene...

Highlights Imugene's partnership with Kincell Bio is aimed at accelerating the development of innovative immunotherapies. Sale of Imugene's North Carolina facility to Kincell Bio would streamline operations and reduce costs. Collabora...

The ASX staged a relief rally on Monday Gold, oil stocks struggled after tensions in the Middle East eased The focus has now shifted from Middle East tensions to company earnings   The ASX put on a relief rally after its -3% loss last wee...

After shedding nearly double what futures had predicted, the ASX200 closed the day 1.8 per cent down. At one stage the ASX was on track for its worst day in 13 months and at the close, real estate, consumer stocks and mining were all lickin...

Australian anti-cancer company Imugene has stamped a strategic manufacturing deal with Kincell Bio, with the latter agreeing to purchase the company’s North Carolina facility for US$6 million (AU$9.34 million).

Highlights The strategic manufacturing and process development collaboration involves the sale of IMU's CGMP manufacturing facility in North Carolina to Kincell. Kincell will acquire the facility for up to US$6 million in upfront and m...

ASX-listed med-tech company Imugene has launched a pivotal expansion study targeting patients with bile tract cancer following encouraging results from its Metastatic Advanced Solid Tumours trial.

There’s no surprises on market today, the ASX200 has been down around half a per cent – on par with the morning’s predictions. The Energy and Materials sectors have been showing resilience, energy’s up about 0.4% and mining stocks by abo...

Atomo announces more purchase orders for HIV Self-Tests Actinogen says first patient was treated in Alzheimer’s disease study Imugene has opened enrolment for expansion study in solid tumours   Atomo sells more HIV self-test kits Atomo Di...

Highlights Bile tract cancer expansion study opens after the completion of the high dose cohort in the MAST trial. This new trial aims to enrol 10 patients with bile tract cancers, specifically cholangiocarcinoma. Interim findings fro...

Cancer immunotherapy company Imugene Ltd (ASX: IMU) will be expanding its trial for the use of CF33-hNIS (VAXINIA) to treat gastrointestinal cancers – including bile tract cancer (also known as (cholangiocarcinoma) – and is now enrolling te...

It's been a decent week for the S&P/ASX 200 Index (ASX: XJO). Since last Thursday, the ASX 200 has gained a healthy 1.05%. But that's nothing compared to the gains of the Liontown Resources Ltd (ASX: LTR) share price. Liontown shares ha...

If you're not averse to investing in the mining sector and want big returns for your portfolio, then read on. That's because analysts at Bell Potter have just put buy ratings on two ASX 300 mining stocks and are tipping potential upside of...

Highlights IMU’s CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx to showcased at the American Association for Cancer Research (AACR) Annual Meeting. The oncolytic virus CF33-hNIS (VAXINIA), either alone or combined...

If you owned S&P/ASX 200 Index (ASX: XJO) lithium stocks in 2021 and 2022, you likely enjoyed some outsized share price gains at the time. That period saw a massive increase in lithium demand amid strong growth in global battery market...

If you're in the market for some new ASX 200 shares in April, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for the month ahead. Two on its list th...

Australian anti-cancer company Imugene has received a patent to protect its unique cancer treatment in China – the largest and most lucrative pharmaceutical market in Asia.

It was a happy Thursday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares today, with investors shaking off the midweek blues that we saw yesterday. By the end of trading this sessi...

The S&P/ASX 200 Index (ASX: XJO) is bouncing back from yesterday's horror session and is pushing higher in afternoon trade. At the time of writing, the benchmark index is up 0.5% to 7,822.5 points. Four ASX shares that are rising more...

Highlights A Notice of Grant received from the Chinese Patent Office for IMU’s oncolytic virotherapy CF33. Previously, grants were obtained in South Korea and Japan. The patents extend protection for the method of composition and meth...

Clinical stage immunooncology company Imugene (ASX:IMU) has received a Notice of Grant from the Chinese Patent Office, following earlier Grants in Japan and South Korea.

Imugene (ASX:IMU) has announced its receipt of a new patent in China. The Chinese regulator – Asia’s largest pharmaceutical market – has approved a patent for Imugene’s oncolytic virotherapy drug CF33. Oncolytic virotherapy relates to...

Imugene Ltd (ASX: IMU) shares are catching the eye on Thursday morning. In early trade, the ASX 300 healthcare stock is up almost 5% to 11 cents. Why is this ASX 300 healthcare stock storming higher? Investors have been buying the clinical...

Changes to government legislation can impact Aussie businesses. That's why staying abreast of proposed changes can be vitally important. Depending on the policy, it can quickly create opportunities and adversities for ASX stocks. In sayi...

Highlights CF33-hNIS (VAXINIA) technology has been selected for an oral presentation at the Cholangiocarcinoma Foundation Annual Conference on 18 April2024. IMU will also showcase a poster during the conference. The conference is sche...

Imugene has cleared the first hurdle in its clinical trial to test the safety and efficacy of its “onCARlytics” treatment for solid tumours after receiving the green light to advance to the combination phase.

Clinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that a Phase 1 clinical trial of lead drug candidate onCARlytics has cleared its first cohort within the intra-tumoural monotherapy arm of the study. Known as OASIS, th...

Dimerix ACTION3 Phase 3 trial successfully passes first interim analysis endpoint Mesoblast says US FDA supports accelerated approval pathway for rexlemestrocel-L Imexhs raises $1.5 million in cap raise to sophisticated and institutional i...

Highlights Phase 1 clinical trial of onCARlytics has moved to the combination arm based on the recommendation of the Cohort Review Committee (CRC). No safety issues were reported in the monotherapy arm of the trial. In the combination...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

A medical mission to flesh out and kill cancerous tumours in humans has received a boost after Imugene intravenously dosed its first patient diagnosed with bile tract cancer as part of a clinical trial.

ASX 200 tech stock Data#3 Limited (ASX: DTL) is floundering on Thursday, down 10.79% to $8.73. The drop follows the release of the business technology solutions company's 1H FY24 report. It was only two days ago that the ASX 200 tech st...

Highlights The first patient has been dosed in the intravenous monotherapy arm of the Phase 1 onCARlytics trial. The patient has been dosed at City of Hope, California. The trial targets to recruit 52 patients with metastatic or advan...

Clinical stage immuno-oncology company Imugene (ASX: IMU) has dosed the first patient in the intravenous monotherapy arm of its Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics. Known as OASIS, the first-in-cl...

    ASX to bounce back after a tech rally in New York Lyft jumps 35pc despite hiccup in earnings release Magnificent Seven over, now time for Sensational Six? The ASX is poised to bounce back on Thursday after a tech rally on Wall Street...

Highlights Positive early signs reported in Phase 1 MAST trial of VAXINIA. VAXINIA received Fast Track Designation from the US FDA for bile duct cancer. In Phase 1 trial for onCARlytics, first patient has been dosed. Phase 1b trial f...

Highlights Oncolytic virus CF33-hNIS (VAXINIA) is IMU’s lead candidate. CF33 and the MAST trial design and targets were presented at international event, ASCO GI Cancers Symposium. Preliminary data has demonstrated encouraging anti-tu...

Highlights First patients dosed in higher dose cohorts, cohort 5 of intratumoral and intravenous monotherapy arm. To date, 24 patients have been dosed in monotherapy arms and no safety issues have been reported. Across both monotherap...

Highlights As of 12 Jan, 38 patients have been dosed with CF33-hNIS virus under the Phase 1 VAXINIA study. The data to be presented this week at ASCO-GI shows that seven gastrointestinal cancer patients who were administered with CF33-...

Highlights IMU is focused on advancing four platform technologies , Allo CAR T cell Therapy, CF33 Oncolytic Virus, onCARlytics and B Cell Immunotherapy. The company is backed by an experienced management team with over 150 years of com...

Many of Australia's top brokers have been busy adjusting their financial models again, leading to the release of a number of broker notes this week. Three ASX shares brokers have named as buys this week are listed below. Here's why they ar...

It's been a tough year for Healius Ltd (ASX: HLS) shares. This ASX 200 healthcare stock has had an exceptionally rough 2023. Until last Wednesday, Healius had lost over 55% over the year to date. The company has had a bit of a bounce-back...

The US Food and Drug Administration has stamped Imugene’s “Vaxinia” virus trials aimed at treating bile duct cancer with “fast-track” status, providing a suite of crucial review and approval priorities.

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.39% to 7,015.20. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify...

The ASX benchmark has ended Tuesday higher 8 of 11 sectors in the green Small caps led by Plenti Group (ASX:PLT), InteliCare (ASX:ICR) The local market has trimmed some of its early gains (wussed out) after jumping out of the blocks in...

It's been a far rosier session for the S&P/ASX 200 Index (ASX: XJO) this Tuesday than what we saw yesterday. In contrast to Monday's rough start to...

Shares rebounded on Tuesday due to gains in real estate and gold, while the Australian dollar reached a four-month high amid expectations of prolonged high borrowing costs compared to other developed nations. Despite a surprise 0.2 percent...

The ASX200 has continued to gather early gains and is up nearly half a per cent – with every sector – except energy – trading in the green. Real estate stocks are strongest today, gaining 1.45 per cent. Energy’s lagging, dropping about .65...